Trade-Ideas: Celgene Corporation (CELG) Is Today's New Lifetime High Stock
- CELG has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $452.6 million.
- CELG has traded 2.1 million shares today.
- CELG is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in CELG with the Ticky from Trade-Ideas. See the FREE profile for CELG NOW at Trade-Ideas More details on CELG: Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. CELG has a PE ratio of 42.0. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold. The average volume for Celgene Corporation has been 3.0 million shares per day over the past 30 days. Celgene has a market cap of $57.6 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.80 and a short float of 1.1% with 1.50 days to cover. Shares are up 76% year to date as of the close of trading on Tuesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Highlights from the ratings report include:
- CELG's revenue growth has slightly outpaced the industry average of 12.5%. Since the same quarter one year prior, revenues rose by 15.0%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- The current debt-to-equity ratio, 0.56, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 2.89, which clearly demonstrates the ability to cover short-term cash needs.
- The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. When compared to other companies in the Biotechnology industry and the overall market, CELGENE CORP's return on equity exceeds that of the industry average and significantly exceeds that of the S&P 500.
- CELGENE CORP' earnings per share from the most recent quarter came in slightly below the year earlier quarter. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, CELGENE CORP increased its bottom line by earning $3.30 versus $2.85 in the prior year. This year, the market expects an improvement in earnings ($5.75 versus $3.30).
- The gross profit margin for CELGENE CORP is currently very high, coming in at 96.22%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 26.28% trails the industry average.
- You can view the full Celgene Corporation Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts